GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LTR Pharma Ltd (ASX:LTP) » Definitions » Liabilities-to-Assets

LTR Pharma (ASX:LTP) Liabilities-to-Assets : 0.00 (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is LTR Pharma Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. LTR Pharma's Total Liabilities for the quarter that ended in Jun. 2023 was A$0.02 Mil. LTR Pharma's Total Assets for the quarter that ended in Jun. 2023 was A$7.51 Mil. Therefore, LTR Pharma's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2023 was 0.00.


LTR Pharma Liabilities-to-Assets Historical Data

The historical data trend for LTR Pharma's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LTR Pharma Liabilities-to-Assets Chart

LTR Pharma Annual Data
Trend Jun21 Jun22 Jun23
Liabilities-to-Assets
1.10 0.21 -

LTR Pharma Semi-Annual Data
Jun21 Jun22 Jun23
Liabilities-to-Assets 1.10 0.21 -

Competitive Comparison of LTR Pharma's Liabilities-to-Assets

For the Biotechnology subindustry, LTR Pharma's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


LTR Pharma's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LTR Pharma's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where LTR Pharma's Liabilities-to-Assets falls into.



LTR Pharma Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

LTR Pharma's Liabilities-to-Assets Ratio for the fiscal year that ended in Jun. 2023 is calculated as:

Liabilities-to-Assets (A: Jun. 2023 )=Total Liabilities/Total Assets
=0.021/7.51
=0.00

LTR Pharma's Liabilities-to-Assets Ratio for the quarter that ended in Jun. 2023 is calculated as

Liabilities-to-Assets (Q: Jun. 2023 )=Total Liabilities/Total Assets
=0.021/7.51
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


LTR Pharma  (ASX:LTP) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


LTR Pharma Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of LTR Pharma's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


LTR Pharma (ASX:LTP) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
9A/204 Alice Street, Brisbane, QLD, AUS, 4000
LTR Pharma Ltd is a clinical stage pharmaceutical company focused on holistically improving men's health, physically and mentally, through the commercialization of an intranasal spray treatment for Erectile Dysfunction. SPONTAN is a Vardenafil-based nasal delivery formulation designed to be a lower dose fast-acting administration that provides a rapid and high availability to a patient's bloodstream compared with the incumbent oral ED treatment products on market.

LTR Pharma (ASX:LTP) Headlines

No Headlines